Amgen Inc. buy melinda
Start price
31.08.17
/
50%
€159.06
Target price
12.09.17
€171.38
Performance (%)
7.96%
End price
12.09.17
€171.72
Summary
This prediction ended on 12.09.17 with a price of €171.72. With a performance of 7.96%, the BUY prediction by melinda for Amgen Inc. closed with a slight gain. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Amgen Inc. | 8.744% | 8.744% | 29.981% | 33.684% |
| iShares Core DAX® | 2.831% | 1.236% | 14.788% | 17.647% |
| iShares Nasdaq 100 | 2.918% | 0.640% | 40.290% | 50.762% |
| iShares Nikkei 225® | 2.007% | -2.135% | 19.861% | 4.937% |
| iShares S&P 500 | 2.257% | 0.451% | 30.090% | 43.940% |
Comments by melinda for this prediction
In the thread Amgen Inc. diskutieren
zu folgen
$
Wenn in Phase III getestet Kopf an Kopf, das Bestreben, reduziert KYPROLIS und Dexamethason das Sterberisiko um 21% und erhöhte die Überlebenszeit von 7,6 Monaten im Vergleich zu Velcade und Dexamethason in Patienten mit rezidivierendem oder refraktärem multiplem Myelom